European health regulator recommends approval for GSK's twice yearly asthma drug

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.

Reuters • Dec 12, 2025

GSK gets EU regulator backing for expanded use of RSV vaccine

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.

Reuters • Dec 12, 2025

GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

Zacks Investment Research • Dec 12, 2025

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive EMA's CHMP opinion for the treatment of certain patients with severe asthma and CRSwNP. And yesterday, the FDA approved Blujepa for the treatment of uncomplicated urogenital gonorrhea.

Seeking Alpha • Dec 12, 2025

US FDA approves GSK's oral treatment for gonorrhea

The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.

Reuters • Dec 11, 2025

GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer

GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.

Zacks Investment Research • Dec 11, 2025

GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?

GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

Zacks Investment Research • Dec 11, 2025

GSK drug for aggressive lung cancer wins US orphan status

GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug Administration granted the treatment Orphan Drug Designation for small-cell lung cancer. The company said the decision was supported by early data from its phase I ARTEMIS-001 study, where some patients with extensive-stage small-cell lung cancer, a form of the disease that has spread widely and is notoriously hard to treat, showed durable responses.

Proactive Investors • Dec 10, 2025

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Oxford, UK and San Jose, California , 10th December 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year, multi-target strategic collaboration with GSK to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.

GlobeNewsWire • Dec 10, 2025

Here's Why GSK (GSK) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 10, 2025